Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes

Jun 08 2023

• By Sarah Karlin-Smith

BIO CEO Rachel King interviewed FDA Commissioner Robert Califf on 7 June 2023 at the BIO International Convention in Boston — BIO CEO Rachel King interviewed FDA Commissioner Robert Califf on 7 June. • Source: Sarah Karlin

Related Content

Accelerated Approval Price Caps: Policy Has High Profile Support – But Can It Be Done?

Feb 01 2023

Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

Mar 20 2023

Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem

Apr 05 2023

FDA’s Califf Speaks Of Tailoring Trials For CMS Evidence Amid Spotlight On Alzheimer’s Drugs

May 24 2023

Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

Jun 02 2023

Additional Topics

United States Pricing Debate Reimbursement FDA Government Payers Medicaid Post Market Regulation & Studies BioPharmaceutical Neurology Metabolic Disorders

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window